Interview with Dr. Michela Cocchi Bianchi is director of international sales for Thereson Srl and innovative technology for neurodegenerative diseases

Press release: Milan (April 21, 2020) – THERESON Srl

Our current position is the Polihub of the Politecnico di Milano. For the uninitiated, the Politecnico di Milano is the largest technical university in Italy, with particular attention to architecture, design and engineering. Polihub is managed by the Milan Polytechnic Foundation. Polihub allows the development of high-tech innovations and inventions (electronics, mechanics, energy, medical devices, robotics, telecommunications) and promotes collaboration initiatives with companies and shareholders. Dr. Bianchi previously worked for Easy International, where she worked to find solutions to pollution from boilers and stationary sources.

What is THERESON and how does it work? What is basic medical technology?
Thereson is an Italian-European biomedical company dedicated to clinical and scientific research. We are particularly interested in the prevention, treatment and containment of vascular, chronic and systemic diseases. In particular, we focus on osteoarticular and musculoskeletal diseases, but we also study podiatric complications due to diabetes. In this regard, we are investing in the development and diffusion of Therapeutic Magnetic Resonance TMR®.

We have assisted through clinical studies that artificially stimulated cell membranes can help repair tissues and organs damaged by trauma and premature aging in certain diseases. Through the use of low frequency and low intensity pulsed magnetic fields, we can improve or even restore biological functioning. Since this applies to degenerative diseases, the positive impact on aging is even stronger in sports performance.

In particular, there are four biological effects of extraordinary interest:

  • Better oxygen supply through reactivation of the microcirculation;
  • Action on protein synthesis;
  • Stabilization of the oxidative balance with consequent reduction of free radicals;
  • The reduction of chronic inflammation.

TMR® helps in the prevention and treatment of many degenerative diseases including:

  • Vascular, arterial, venous and lymphatic pathologies;
  • Decubitus ulcers;
  • Podiatric complications due to diabetes;
  • Post-surgical wounds;
  • Osteoarticular pathologies (arthrosis, arthritis, osteoporosis, joint stiffness and fractures).

Thereson has already invested over 6 million euros in research that has allowed us not only to publish, but to treat tens of thousands of patients in the hospital, at home and in both amateur and professional sports fields.

In terms of IP protection, what strategies have been implemented?
Our first strategy was to adopt and create several patents capable of protecting individual frequencies and subsequent grouping into packages and sequences / trains. Our future strategy will be to focus on packaging these frequency groups into programs for individual pathologiesali.

Read the full INTERVIEW: